|
Best Friends Grooming Message Board >
Which Patients Should Avoid Vilitra 40?
Which Patients Should Avoid Vilitra 40?
Post all your Pet Questions, Comments, Tips, Suggestions, Events, Promotions Here!
Page:
1
Guest
Guest
Jan 29, 2025
12:50 AM
|
Vilitra 40 (containing Vardenafil 40 mg) is a medication used to treat erectile dysfunction (ED). However, certain patients should avoid taking it due to the potential for serious side effects or interactions with underlying health conditions. The following groups of patients should avoid Vilitra 40 or use it with caution, under the supervision of a healthcare provider:
1. Patients Taking Nitrate Medications:
Avoid Vilitra 40 if you are taking nitrate medications (e.g., nitroglycerin, isosorbide dinitrate), commonly prescribed for chest pain (angina) or heart conditions. The combination of Vardenafil and nitrates can lead to a severe and dangerous drop in blood pressure, which can cause dizziness, fainting, or even a heart attack or stroke.
2. Patients with Severe Heart Conditions:
Heart disease: Those with a history of severe heart problems, such as heart attack, heart failure, or irregular heartbeats, should avoid using Vilitra 40 without consulting a healthcare provider. PDE5 inhibitors like Vardenafil can slightly lower blood pressure, which could be risky for individuals with unstable heart conditions.
Stroke or recent heart attack: Individuals who have had a stroke or heart attack within the last 6 months should generally avoid PDE5 inhibitors unless approved by a healthcare provider.
3. Patients with Severe Liver or Kidney Problems:
Liver disease: Those with severe liver conditions (e.g., cirrhosis, liver failure) should avoid VILITRA 40 MG as the liver metabolizes the medication. Impaired liver function can lead to higher blood levels of Vardenafil, increasing the risk of side effects.
Kidney disease: Individuals with severe kidney dysfunction or those on dialysis may need a dosage adjustment or may be advised against taking Vilitra 40 due to potential accumulation of the drug in the system.
4. Patients with Low Blood Pressure:
Hypotension (low blood pressure): Patients with a history of low blood pressure (systolic pressure below 90 mm Hg or diastolic pressure below 60 mm Hg) should avoid Vilitra 40, as it can further lower blood pressure, leading to dizziness, fainting, or other cardiovascular complications.
5. Patients with Retinal Disorders or Vision Problems:
Non-arteritic anterior ischemic optic neuropathy (NAION): Individuals with a history of NAION, a condition that causes vision loss, or other eye-related conditions like retinitis pigmentosa should avoid using Vilitra 40. PDE5 inhibitors have been associated with a rare but serious risk of sudden vision loss in some cases.
6. Patients with Allergies to Vardenafil or Any Component of the Medication:
If you are allergic to Vardenafil or any other ingredients in Vilitra 40, you should avoid using this medication.
7. Patients with Severe Deformities of the Penis:
Men with penile deformities (such as Peyronie’s disease) or those with priapism (prolonged erections) should avoid using Vilitra 40 unless specifically directed by a healthcare provider, as it can potentially worsen these conditions.
8. Patients Who Are Taking Other PDE5 Inhibitors:
Avoid combining Vilitra 40 with other medications that also contain PDE5 inhibitors (e.g., Viagra, Cialis, or Levitra), as this increases the risk of side effects like dangerously low blood pressure or prolonged erections.
9. Patients Who Are Pregnant or Breastfeeding:
Vilitra 40 is not intended for use in women, including those who are pregnant or breastfeeding. Its safety and efficacy in women have not been established.
10. Patients with a History of Priapism:
Men with a history of priapism, a condition involving a prolonged and painful erection lasting more than 4 hours, should exercise caution or avoid using Vilitra 40. This condition can lead to permanent damage to the penis if not treated immediately.
Always consult a healthcare provider before starting Vilitra 40 to ensure it is safe based on your medical history and current medications.
If you experience any severe side effects such as vision changes, chest pain, or prolonged erection (lasting more than 4 hours), seek medical attention immediately.
Conclusion: While Vilitra 40 is an effective treatment for erectile dysfunction, it should be used with caution or avoided in individuals with certain health conditions. Always consult a healthcare provider before starting any new medication, especially if you have a history of heart disease, liver or kidney problems, low blood pressure, or other serious conditions.
|
Post a Message
| |
|
|
| |
| |
| CLICK ON BANNERS TO VISIT EACH ONLINE MAGAZINE - SOME ARE IN THE CONSTRUCTION PHASE AND WILL BE ONLINE SOON |
| |
| |
|
|
| |
| |
| |
|
|
| |
| |
| |
|
|
| |
| © Copyright 2016 All Photos by Ed and Wayne from The Long Island Web / Website Designed and Managed by Clubhouse2000 |
| |
|
* The Long Island Network is an online resource for events, information, opinionated material, and links to the content of other websites and social media and cannot be held responsible for their content in any way, but will attempt to monitor content not suitable for our visitors. Some content may not be suitable for children without supervision from an adult. Mature visitors are more than welcome. Articles by the Editor will be opinions from an independent voice who believes the U.S. Constitution is our sacred document that insures our Inalienable Rights to Liberty and Freedom.
|
| |
| Disclaimer: The Advertisers and Resources found on this website may or may not agree with the political views of the editor and should not be held responsible for the views of The Long Island Network or its affiliates. The Long Island Network was created to promote, advertise, and market all businesses in the Long Island Network regardless of their political affiliation. |
| |
|
All rights reserved and copyrighted 2023
Thepetservicesweb.com is an affiliate of The Long Island Network
|
| |
| |
| Accessibilty Statement |
| |
|
|
|
|
